Randomized controlled trial of 8 weeks' vs 12 weeks' interval between neoadjuvant chemoradiotherapy and surgery for locally advanced rectal cancer

Simple item page
dc.contributor.authorTerzi, Cem
dc.contributor.authorBingül, Muhammet Bahattin
dc.contributor.authorArslan, Naciye Çiğdem
dc.contributor.authorCanda, Aras Emre
dc.contributor.authorObuz, Funda
dc.contributor.authorGörken, İlknur Birkay
dc.contributor.authorÜnlü, Mehtat
dc.contributor.authorÖztop, İlhan
dc.contributor.buuauthorIşık, Özgen
dc.contributor.buuauthorYılmazlar, Tuncay
dc.contributor.buuauthorUğraş, Nesrin
dc.contributor.buuauthorKanat, Özkan
dc.contributor.buuauthorÖztürk, Ersin
dc.contributor.buuauthorKurt, Malerie
dc.contributor.departmentBursa Uludağ Üniversitesi/Tıp Fakültesi/Cerrahi Tıp Bilimleri/Genel Cerrahi Bölümü.tr_TR
dc.contributor.orcid0000-0002-9541-5035tr_TR
dc.contributor.orcid0000-0002-9541-5035tr_TR
dc.contributor.researcheridP-5779-2019tr_TR
dc.contributor.researcheridAAW-9602-2020tr_TR
dc.contributor.researcheridABH-2238-2021tr_TR
dc.contributor.researcheridAAH-2716-2021tr_TR
dc.contributor.scopusid36600543700tr_TR
dc.contributor.scopusid6701800362tr_TR
dc.contributor.scopusid55386535600tr_TR
dc.contributor.scopusid55881548500tr_TR
dc.contributor.scopusid35070171400tr_TR
dc.contributor.scopusid8843050600tr_TR
dc.date.accessioned2022-12-27T11:12:48Z
dc.date.available2022-12-27T11:12:48Z
dc.date.issued2019-09-30
dc.description.abstractAim The aim was to compare the pathological complete response (pCR) rate at 8 compared to 12 weeks' interval between completion of neoadjuvant chemoradiotherapy (CRT) and surgery in patients with locally advanced rectal cancer. Method This was a randomized trial which included a total of 330 patients from two institutions. Patients with locally advanced (T3-4N0M0, TxN+M0) rectal cancer were randomized into 8- and 12-week interval groups. All the patients received long-course CRT (45 Gy in 1.8 Gy fractions and concomitant oral capecitabine or 5-fluorouracil infusion). Surgery was performed at either 8 or 12 weeks after CRT. The primary end-point was pCR. Secondary end-points were sphincter preservation, postoperative morbidity and mortality. Results Two-hundred and fifty-two patients (n = 125 in the 8-week group, n = 127 in the 12-week group) were included. Demographic and clinical characteristics were similar between groups. The overall pCR rate was 17.9% (n = 45): 12% (n = 15) in the 8-week group and 23.6% (n = 30) in the 12-week group (P = 0.021). Sphincter-preserving surgery was performed in 107 (85.6%) patients which was significantly higher than the 94 (74%) patients in the 12-week group (P = 0.016). Postoperative mortality was seen in three (1.2%) patients overall and was not different between groups (1.6% in 8 weeks vs 0.8% in 12 weeks, P = 0.494). Groups were similar in anastomotic leak (10.8% in 8 weeks vs 4.5% in 12 weeks, P = 0.088) and morbidity (30.4% in 8 weeks and 20.1% in 12 weeks, P = 0.083). Conclusion Extending the interval between CRT and surgery from 8 to 12 weeks resulted in a 2-fold increase in pCR rate without any difference in mortality and morbidity.en_US
dc.identifier.citationTerzi, C. vd. (2019). ''Randomized controlled trial of 8 weeks' vs 12 weeks' interval between neoadjuvant chemoradiotherapy and surgery for locally advanced rectal cancer''. Colorectal Disease, 22(3), 279-288.en_US
dc.identifier.endpage288tr_TR
dc.identifier.issn1462-8910
dc.identifier.issn1463-1318
dc.identifier.issue3tr_TR
dc.identifier.pubmed31566843tr_TR
dc.identifier.scopus2-s2.0-85074361458tr_TR
dc.identifier.startpage279tr_TR
dc.identifier.urihttps://doi.org/10.1111/codi.14867
dc.identifier.urihttps://onlinelibrary.wiley.com/doi/10.1111/codi.14867
dc.identifier.urihttp://hdl.handle.net/11452/30117
dc.identifier.volume22tr_TR
dc.identifier.wos000491010400001tr_TR
dc.indexed.pubmedPubMeden_US
dc.indexed.scopusScopusen_US
dc.indexed.wosSCIEen_US
dc.language.isoenen_US
dc.publisherWileyen_US
dc.relation.journalColorectal Diseaseen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergitr_TR
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectGastroenterology & hepatologyen_US
dc.subjectSurgeryen_US
dc.subjectRectal canceren_US
dc.subjectNeoadjuvant chemoradiotherapyen_US
dc.subjectIntervalen_US
dc.subjectComplete responseen_US
dc.subjectPathological complete responseen_US
dc.subjectRadiation-therapyen_US
dc.subjectAdenocarcinomaen_US
dc.subjectRecommendationsen_US
dc.subjectResectionen_US
dc.subject.emtreeCapecitabineen_US
dc.subject.emtreeFluorouracilen_US
dc.subject.emtreeAntineoplastic agenten_US
dc.subject.emtreeAdjuvant chemoradiotherapyen_US
dc.subject.emtreeAdulten_US
dc.subject.emtreeAdvanced canceren_US
dc.subject.emtreeAnastomosis leakageen_US
dc.subject.emtreeArticleen_US
dc.subject.emtreeControlled studyen_US
dc.subject.emtreeFemaleen_US
dc.subject.emtreeHumanen_US
dc.subject.emtreeMajor clinical studyen_US
dc.subject.emtreeMaleen_US
dc.subject.emtreeNeoadjuvant chemotherapyen_US
dc.subject.emtreeOrgan preservationen_US
dc.subject.emtreePriority journalen_US
dc.subject.emtreeRandomized controlled trialen_US
dc.subject.emtreeRectum canceren_US
dc.subject.emtreeSigmoidoscopyen_US
dc.subject.emtreeSphincteren_US
dc.subject.emtreeSurgical mortalityen_US
dc.subject.emtreeTreatment durationen_US
dc.subject.emtreeTreatment responseen_US
dc.subject.emtreeTumor localizationen_US
dc.subject.emtreeCancer stagingen_US
dc.subject.emtreeChemoradiotherapyen_US
dc.subject.emtreeNeoadjuvant therapyen_US
dc.subject.emtreePathologyen_US
dc.subject.emtreeRectumen_US
dc.subject.emtreeRectum tumoren_US
dc.subject.emtreeTreatment outcomeen_US
dc.subject.meshAntineoplastic combined chemotherapy protocolsen_US
dc.subject.meshCapecitabineen_US
dc.subject.meshChemoradiotherapyen_US
dc.subject.meshFluorouracilen_US
dc.subject.meshHumansen_US
dc.subject.meshNeoadjuvant therapyen_US
dc.subject.meshNeoplasm stagingen_US
dc.subject.meshRectal neoplasmsen_US
dc.subject.meshRectumen_US
dc.subject.meshTreatment outcomeen_US
dc.subject.scopusRectum Tumor; Chemoradiotherapy; Neoadjuvant Therapyen_US
dc.subject.wosGastroenterology & hepatologyen_US
dc.subject.wosSurgeryen_US
dc.titleRandomized controlled trial of 8 weeks' vs 12 weeks' interval between neoadjuvant chemoradiotherapy and surgery for locally advanced rectal canceren_US
dc.typeArticle
dc.wos.quartileQ2 (Surgery)en_US
dc.wos.quartileQ3 (Gastroenterology & hepatology)en_US

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Arslan_vd_2019.pdf
Size:
291.84 KB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Web of Science
PubMed
Scopus